Trial Outcomes & Findings for Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID (NCT NCT04349371)
NCT ID: NCT04349371
Last Updated: 2025-02-27
Results Overview
Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR. This is to determine/measure the clinical efficacy of CQ in healthcare workers.
TERMINATED
PHASE2
5 participants
Up to 3 months
2025-02-27
Participant Flow
The study was terminated before participants could be assigned to any Arm. There were 5 participants who signed informed consent form: 3 participants withdrew, and 2 participants did not proceed due to study termination.
Participant milestones
| Measure |
CQ Group
The study was terminated before participants could be assigned to any Arm. Per protocol, participants will receive CQ supply for 3 months.
|
Placebo Group
The study was terminated before participants could be assigned to any Arm. Per protocol, participants will receive placebo supply for 3 months.
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: Up to 3 monthsPopulation: The study was terminated before participants could be assigned to any Arm. Data was therefore not collected or analyzed.
Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR. This is to determine/measure the clinical efficacy of CQ in healthcare workers.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 3 monthsPopulation: The study was terminated before participants could be assigned to any Arm. Data was therefore not collected or analyzed.
This is to measure the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status. The number of severe illnesses in at risk healthcare workers and patients with adverse events grade 3 or higher and GI intolerance will be tallied.
Outcome measures
Outcome data not reported
Adverse Events
CQ and Placebo Group
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place